These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 25696803

  • 1. VE1 antibody is not highly specific for the BRAF V600E mutation in thyroid cytology categories with the exception of malignant cases.
    Lee SR, Yim H, Han JH, Lee KB, Lee J, Soh EY, Kim DJ, Chung YS, Jeong SY, Sheen SS, Park SH, Kim JH.
    Am J Clin Pathol; 2015 Mar; 143(3):437-44. PubMed ID: 25696803
    [Abstract] [Full Text] [Related]

  • 2. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED, Martini M, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM.
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [Abstract] [Full Text] [Related]

  • 3. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
    Paek SH, Kim BS, Kang KH, Kim HS.
    World J Surg Oncol; 2017 Nov 13; 15(1):202. PubMed ID: 29132392
    [Abstract] [Full Text] [Related]

  • 4. Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience.
    Rossi ED, Bizzarro T, Martini M, Capodimonti S, Fadda G, Larocca LM, Schmitt F.
    Cancer Cytopathol; 2014 Dec 13; 122(12):883-91. PubMed ID: 25156883
    [Abstract] [Full Text] [Related]

  • 5. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
    Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park DJ, Lee HS, Cho BY, Lee ES, Kim SW.
    Clin Endocrinol (Oxf); 2006 Nov 13; 65(5):660-6. PubMed ID: 17054470
    [Abstract] [Full Text] [Related]

  • 6. [Value of the detection of BRAF(V600E) gene mutation and protein expression in auxiliary cytological diagnosis of papillary thyroid carcinoma].
    Zhao H, Guo HQ, Zhang ZH, Cao J, Zhao LL, Sun Y, Wang C, Xiao T.
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jan 07; 54(1):18-22. PubMed ID: 30704164
    [Abstract] [Full Text] [Related]

  • 7. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.
    Wobker SE, Kim LT, Hackman TG, Dodd LG.
    Cancer Cytopathol; 2015 Sep 07; 123(9):531-9. PubMed ID: 26080065
    [Abstract] [Full Text] [Related]

  • 8. Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?
    Kloos RT, Reynolds JD, Walsh PS, Wilde JI, Tom EY, Pagan M, Barbacioru C, Chudova DI, Wong M, Friedman L, LiVolsi VA, Rosai J, Lanman RB, Kennedy GC.
    J Clin Endocrinol Metab; 2013 Apr 07; 98(4):E761-8. PubMed ID: 23476074
    [Abstract] [Full Text] [Related]

  • 9. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
    Crescenzi A, Guidobaldi L, Nasrollah N, Taccogna S, Cicciarella Modica DD, Turrini L, Nigri G, Romanelli F, Valabrega S, Giovanella L, Onetti Muda A, Trimboli P.
    Horm Metab Res; 2014 May 07; 46(5):370-4. PubMed ID: 24570209
    [Abstract] [Full Text] [Related]

  • 10. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status.
    Kim SK, Hwang TS, Yoo YB, Han HS, Kim DL, Song KH, Lim SD, Kim WS, Paik NS.
    J Clin Endocrinol Metab; 2011 Mar 07; 96(3):658-64. PubMed ID: 21239517
    [Abstract] [Full Text] [Related]

  • 11. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
    Ohori NP, Singhal R, Nikiforova MN, Yip L, Schoedel KE, Coyne C, McCoy KL, LeBeau SO, Hodak SP, Carty SE, Nikiforov YE.
    Cancer Cytopathol; 2013 Apr 07; 121(4):197-205. PubMed ID: 22887810
    [Abstract] [Full Text] [Related]

  • 12. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
    Lee ST, Kim SW, Ki CS, Jang JH, Shin JH, Oh YL, Kim JW, Chung JH.
    J Clin Endocrinol Metab; 2012 Jul 07; 97(7):2299-306. PubMed ID: 22500044
    [Abstract] [Full Text] [Related]

  • 13. Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens.
    Meng Z, Lu J, Wu H, Zhao Y, Luo Y, Gao J, Zhu Q, Jiang Y, Li W, Liang Z.
    Tumour Biol; 2016 Jan 07; 37(1):611-8. PubMed ID: 26240026
    [Abstract] [Full Text] [Related]

  • 14. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
    Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A.
    Acta Neuropathol; 2011 Jul 07; 122(1):11-9. PubMed ID: 21638088
    [Abstract] [Full Text] [Related]

  • 15. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
    Adeniran AJ, Hui P, Chhieng DC, Prasad ML, Schofield K, Theoharis C.
    Acta Cytol; 2011 Jul 07; 55(6):570-5. PubMed ID: 22156468
    [Abstract] [Full Text] [Related]

  • 16. Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing.
    Lee SR, Jung CK, Kim TE, Bae JS, Jung SL, Choi YJ, Kang CS.
    Thyroid; 2013 Nov 07; 23(11):1416-22. PubMed ID: 23590130
    [Abstract] [Full Text] [Related]

  • 17. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
    Hyeon J, Ahn S, Shin JH, Oh YL.
    Cancer Cytopathol; 2014 May 07; 122(5):368-76. PubMed ID: 24591408
    [Abstract] [Full Text] [Related]

  • 18. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
    Zimmermann AK, Camenisch U, Rechsteiner MP, Bode-Lesniewska B, Rössle M.
    Cancer Cytopathol; 2014 Jan 07; 122(1):48-58. PubMed ID: 24039206
    [Abstract] [Full Text] [Related]

  • 19. Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology.
    Johnson SJ, Hardy SA, Roberts C, Bourn D, Mallick U, Perros P.
    Cytopathology; 2014 Jun 07; 25(3):146-54. PubMed ID: 24417615
    [Abstract] [Full Text] [Related]

  • 20. BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for diagnosis of thyroid nodules: The influence of false-positive and false-negative results.
    Zhao CK, Zheng JY, Sun LP, Xu RY, Wei Q, Xu HX.
    Cancer Med; 2019 Sep 07; 8(12):5577-5589. PubMed ID: 31397092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.